Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Novel Drug Development Opportunities in Autoimmune Diseases
Novel Drug Development Opportunities in Autoimmune Diseases

Ocular SystemRespiratory SystemNervous SystemDigestive SystemCardio-vascular SystemUrinary SystemEndocrine SystemHematological SystemReproductive SystemSkin & Connective Tissue SystemMuscular SystemSkeletal & Joint System

Autoimmune diseases are a group of debilitating conditions characterized by the body's immune system mistakenly attacking its own healthy cells, tissues, and organs. This immunological dysregulation stems from a breakdown in self-tolerance mechanisms, resulting in an aberrant immune response that causes inflammation and tissue damage.

These diseases can be classified into two main types based on the range of organs and tissues affected:

Organ-Specific Autoimmune Diseases: These disorders target a single organ or tissue type, such as Multiple Sclerosis, Autoimmune Hepatitis, and Type 1 Diabetes Mellitus.

Systemic Autoimmune Diseases: In this category, the autoimmune assault extends to multiple organs and systems. Prominent diseases include Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis, Ankylosing Spondylitis, Sjogren's Syndrome, Polymyositis, and Dermatomyositis.

At ACROBiosystems, we are committed to providing comprehensive products and solutions to accelerate autoimmune disease drug discovery and development. Our innovative product portfolio encompasses high-quality recombinant proteins, functional cell lines, antibodies, and testing kits autoimmune disease targets. These products and solutions are designed to facilitate various stages of the biological drug development pipeline, empowering researchers to advance promising therapies efficiently.

Autoimmune Diseases Guide

Ocular System
Respiratory System
Digestive System
Urinary System
Skin & Connective Tissue System
Skeletal & Joint System
Nervous System
Cardio-vascular System
Hematological System
Endocrine System
Reproductive System
Muscular System
Ocular System
Respiratory System
Digestive System
Urinary System
Skin & Connective Tissue System
Skeletal & Joint System
Nervous System
Cardio-vascular System
Hematological System
Endocrine System
Reproductive System
Muscular System

Hot Products in Autoimmune Disease Drug Development

Pathogenesis of Psoriasis - JAK-STAT Signaling Pathway
Pathogenesis of Psoriasis - JAK-STAT Signaling Pathway1
Psoriasis
Protein Targets
TNF-alpha, TNF-beta, JAK1, IL-12, IL-17, TYK2
hand
Mechanism of Systemic Sclerosis
Mechanism of Systemic Sclerosis2
Systemic Sclerosis
Protein Targets
TNF-alpha, TNF-beta, CD19, ETAR, IL-6, IL-17
hand
Pathogenesis of Dermatomyositis
Pathogenesis of Dermatomyositis3
Dermatomyositis
Protein Targets
TNF-alpha, JAK1, CD19, CD80, CD86, TYK2
hand
Pathogenesis of Crohn’s Disease
Pathogenesis of Crohn’s Disease4
Crohn’s Disease
Protein Targets
TL1A, TNF-alpha, ITG-A4B1, ITG-A4B7, IL-12, IL-23
hand
Pathophysiological Mechanisms of Ulcerative Colitis
Pathophysiological Mechanisms of Ulcerative Colitis5
Ulcerative Colitis
Protein Targets
TL1A, TNF-alpha, JAK1, ITG-A4B7, IL-12, IL-23, IFNAR
hand
Pathogenesis of Multiple Sclerosis
Pathogenesis of Multiple Sclerosis6
Multiple Sclerosis
Protein Targets
BTK, CD20, ITG-A4B1, ITG-A4B7, IL-12
hand
The Pathophysiological Mechanisms of Myasthenia Gravis at the Neuromuscular Junction
The Pathophysiological Mechanisms of Myasthenia Gravis at the Neuromuscular Junction7
Myasthenia Gravis
Protein Targets
BAFF, CD19, CD20, FCGRT, IgG Fc, ACHE
hand
Pathogenic Effects of Type 1 Diabetes on Beta Cells
Pathogenic Effects of Type 1 Diabetes on Beta Cells8
Type I Diabetes
Protein Targets
INSR, GLP1R, GIPR, GCGR, DPP4, TNF-aplha
hand
Pathogenesis of Idiopathic pulmonary fibrosis
Pathogenesis of Idiopathic pulmonary fibrosis9
Idiopathic pulmonary fibrosis
Protein Targets
ETAR, ETBR, IFNGR, ITG-AVB6, TGF-β, VEGFR
hand
Activation of JAK/STAT Signaling Pathways in Interstitial Lung Disease
Activation of JAK/STAT Signaling Pathways in Interstitial Lung Disease10
Interstitial lung disease
Protein Targets
CD20, ETAR, ETBR, FGF R, TNF-alpha, VEGFR
hand
Signaling Pathway in Rheumatoid Arthritis
Signaling Pathway in Rheumatoid Arthritis11
Rheumatoid Arthritis
Protein Targets
TNF-alpha, TNF-beta, CD20, IL-6, IL-17, JAK1
hand
Primary Pathways in the Pathogenesis of SLE
Primary Pathways in the Pathogenesis of SLE12
Systemic Lupus Erythematosus
Protein Targets
BAFF, CD19, CD20, CD38, CD40, IL-2
hand

If you have any needs or more development suggestions,please contact us

Reference

Reference:
  • 1. ZHU Yu-yu, SONG Cheng-lin, SUN Yang. Advances in mechanisms for psoriasis and drug regulation. Acta Pharmaceutica Sinica, 2020, 55(7): 1393-1400.

  • 2. Fuschiotti P. Current perspectives on the immunopathogenesis of systemic sclerosis. Immunotargets Ther. 2016;5:21-35 .

  • 3. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003 Sep 20;362(9388):971-82.

  • 4. Roda, G., Chien Ng, S., Kotze, P.G. et al. Crohn’s disease. Nat Rev Dis Primers 6, 22 (2020).

  • 5. Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet. 2012 Nov 3;380(9853):1606-19.

  • 6. Cervantes-Gracia, K., Husi, H. Integrative analysis of Multiple Sclerosis using a systems biology approach. Sci Rep 8, 5633 (2018).

  • 7. Gilhus, N.E., Tzartos, S., Evoli, A. et al. Myasthenia gravis. Nat Rev Dis Primers 5, 30 (2019).

  • 8. Zajec A, Trebušak Podkrajšek K, Tesovnik T, Šket R, Čugalj Kern B, Jenko Bizjan B, Šmigoc Schweiger D, Battelino T, Kovač J. Pathogenesis of Type 1 Diabetes: Established Facts and New Insights. Genes (Basel). 2022 Apr 16;13(4):706.

  • 9. Inui N, Sakai S, Kitagawa M. Molecular Pathogenesis of Pulmonary Fibrosis, with Focus on Pathways Related to TGF-β and the Ubiquitin-Proteasome Pathway. Int J Mol Sci. 2021 Jun 5;22(11):6107.

  • 10. Montero, P.; Milara, J.; Roger, I.; Cortijo, J. Role of JAK/STAT in Interstitial Lung Diseases; Molecular and Cellular Mechanisms. Int. J. Mol. Sci. 2021, 22, 6211.

  • 11. Zhu, M.; Ding, Q.; Lin, Z.; Fu, R.; Zhang, F.; Li, Z.; Zhang, M.; Zhu, Y. New Targets and Strategies for Rheumatoid Arthritis: From Signal Transduction to Epigenetic Aspect. Biomolecules 2023, 13, 766.

  • 12. Batu, Ezgi. (2018). Monogenic systemic lupus erythematosus: insights in pathophysiology. Rheumatology International. 38. 10.1007/s00296-018-4048-7.

ACRO Quality

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message